Palisade Bio (PALI) stock
PALI's Quality Score was unchanged on Mon, Oct 5, at -7.
Follow PALI's trial news. Pro members can get an alert when Palisade Bio files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for PALI, and how long its cash lasts
From Palisade Bio’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
Over 5 years
Dilution on the horizon
- Shelf registration (S-3, filed May 12, 2026)
- At-the-market share sales program (S-3, filed May 12, 2026)
Insiders
Director Robert Baltera Jr. bought 45,000 shares on Jul 9. 8 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 25 daysINOInovio Pharmaceuticals
INOINO-3107
- In 36 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 48 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 29% in 3 months, 25% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−3Long-term trend below a falling 200-day average, down over one year, down over two years
5 more things pulling PALI's score down, for Pro members
What's next
Expected to report Mon Nov 9, after the close
After its last 2 reports it closed -0.3% on average, higher 1 of 2 times.
What would turn PALI's score around: 8 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
PALI has 2 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1435.8
- MACD (12, 26, 9)Below signal
- 50-day average$1.91
- 200-day average$1.91
- ADX 1435.4
- Support$1.45
- Resistance$1.84
- Bollinger Bands (20, 2)Inside
- Volume0.4x
How PALI ranks in Biotech
PALI is #264 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
ORKAOpen for its score
OSTXOpen for its score
PBLSOpen for its score
PBYIOpen for its score
PALI2/14-6
When does PALI report earnings, and what happens after?
Expected to report Mon Nov 9, after the close (in 35 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 10, 2026After close | After close | -2.4% | +1.9% | +2.4% |
| May 12, 2026After close | After close | 0.0% | -2.6% | -5.7% |
Who is trading PALI
PALI insider trades
2 insiders bought $279K across 8 filings, and 2 insiders sold $410K across 2 filings, in the last 6 months. The newest:
About Palisade Bio
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of PALI's score, with the points and the reason
- All 14 checks on PALI and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on PALI
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.